Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2022 | Prognostic biomarkers for prostate cancer

Fred Saad • 11 Sep 2022
ESMO 2022
Prostate Cancer

Fred Saad, MD, FRCS, University of Montreal Hospital Center, Montreal, Canada, discusses prognostic biomarkers for prostate cancer, the most common being volume of metastatic disease, site of metastatic disease and the presence of visceral metastases. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Fred Saad

1:19
Highlights in prostate cancer from ESMO
Fred Saad • 11 Sep 2022
1:26
Current standards and future prospects for the treatment of hormone refractory prostate cancer
Fred Saad • 11 Sep 2022
2:45
Biomarker analysis and updated results from PROpel
Fred Saad • 11 Sep 2022
1:34
Combination therapies for the treatment of prostate cancer
Fred Saad • 17 Feb 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals